MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 13, 2005; DOI: 10.1124/mol.105.012005


0026-895X/05/6804-974-982$20.00
Mol Pharmacol 68:974-982, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.012005v1
68/4/974    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunlop, J.
Right arrow Articles by Butera, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunlop, J.
Right arrow Articles by Butera, J.

Characterization of Novel Aryl-Ether, Biaryl, and Fluorene Aspartic Acid and Diaminopropionic Acid Analogs as Potent Inhibitors of the High-Affinity Glutamate Transporter EAAT2

John Dunlop, H. Beal McIlvain, Tikva A. Carrick, Brian Jow, Qiang Lu, Dianne Kowal, Steven Lin, Alexander Greenfield, Cristina Grosanu, Kristi Fan, Robert Petroski, John Williams, Alan Foster, and John Butera

Discovery Neuroscience (J.D., H.B.M., T.A.C., B.J., Q.L., D.K., S.L.) and Chemical & Screening Sciences (A.G., C.G., K.F., J.B.), Wyeth Research, Princeton, New Jersey; and Neurocrine Biosciences, San Diego, California (R.P., J.W., A.F.)

In this study, we describe the pharmacological characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of EAAT2, the predominant glutamate transporter in forebrain regions. The rank order of potency determined for the inhibition of human EAAT2 was N4-[4-(2-bromo-4,5-difluorophenoxy)phenyl]-L-asparagine (WAY-213613) (IC50 = 85 ± 5 nM) > N4-(2'-methyl-1,1'-biphenyl-4-yl)-L-asparagine (WAY-213394) (IC50 = 145 ± 22 nM) = N4-[7-(trifluoromethyl)-9H-fluoren-2-yl]-L-asparagine (WAY-212922) (IC50 = 157 ± 11 nM) = 3-{[(4'-chloro-2-methyl-1,1'-biphenyl-4-yl)carbonyl]amino}-L-alanine (WAY-211686) (IC50 = 190 ± 10 nM). WAY-213613 was the most selective of the compounds examined, with IC50 values for inhibition of EAAT1 and EAAT3 of 5 and 3.8 µM, respectively, corresponding to a 59- and 45-fold selectivity toward EAAT2. An identical rank order of potency [WAY-213613 (35 ± 7 nM) > WAY-213394 (92 ± 13 nM) = WAY-212922 (95 ± 8 nM) = WAY-211686 (101 ± 20 nM)] was observed for the inhibition of glutamate uptake in rat cortical synaptosomes, consistent with the predominant contribution of EAAT2 to this activity. Kinetic studies with each of the compounds in synaptosomes revealed a competitive mechanism of inhibition. All compounds were determined to be nonsubstrates by evaluating both the stimulation of currents in EAAT2-injected oocytes and the heteroexchange of D-[3H]aspartate from cortical synaptosomes. WAY-213613 represents the most potent and selective inhibitor of EAAT2 identified to date. Taken in combination with its selectivity over ionotropic and metabotropic glutamate receptors, this compound represents a potential tool for the further elucidation of EAAT2 function.


Received February 14, 2005; accepted July 13, 2005

Address correspondence to: Dr. John Dunlop, Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, NJ 08543. E-mail: dunlopj{at}wyeth.com




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
K. Shimamoto, Y. Otsubo, Y. Shigeri, Y. Yasuda-Kamatani, M. Satoh, S. Kaneko, and T. Nakagawa
Characterization of the Tritium-Labeled Analog of L-threo-beta-Benzyloxyaspartate Binding to Glutamate Transporters
Mol. Pharmacol., January 1, 2007; 71(1): 294 - 302.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics